Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Juanjuan Zhao¹, Yongping Song¹, Delong Liu^{1

2}

Affiliations

¹ 1Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² 2Division of Hematology and Oncology, New York Medical College, Valhalla, USA.

Published Erratum

Juanjuan Zhao et al. Biomark Res. 2019.

. 2019 Oct 17:7:21.

doi: 10.1186/s40364-019-0172-0. eCollection 2019.

Juanjuan Zhao¹, Yongping Song¹, Delong Liu^{1

2}

¹ 1Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² 2Division of Hematology and Oncology, New York Medical College, Valhalla, USA.

Abstract

[This corrects the article DOI: 10.1186/s40364-019-0170-2.].

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J, Song Y, Liu D. Zhao J, et al. Biomark Res. 2019 Sep 11;7:19. doi: 10.1186/s40364-019-0170-2. eCollection 2019. Biomark Res. 2019. PMID: 31528345 Free PMC article. Review.

1. Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. doi: 10.1186/s40364-019-0170-2. - DOI - PMC - PubMed